Urolithin A vs NMN vs NR: Which Longevity Molecule Is Right for You?

Urolithin A, NMN, and NR are three of the most talked-about molecules in cellular aging. They are often lumped together, but they work on different parts of the same machine. Here is how each one actually functions, what the human evidence shows, and how to think about which belongs in your routine.

The quick version

All three compounds aim at the mitochondria, the tiny structures inside your cells that turn food and oxygen into usable energy. But they approach the problem from opposite ends. Urolithin A works largely on housekeeping — helping cells recycle worn-out mitochondria so the remaining pool runs cleaner. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are both precursors to NAD+, a coenzyme that mitochondria and hundreds of enzymes depend on to run their chemistry. Put simply: urolithin A is about clearing out damaged components, while NMN and NR are about refilling a fuel-line molecule. Because they target different steps, comparing them is less “which is best” and more “what are you trying to support.”

What is urolithin A?

Urolithin A is a postbiotic — a compound your gut bacteria produce when they break down ellagitannins and ellagic acid from foods like pomegranates, walnuts, and certain berries. You do not get urolithin A directly from these foods; your microbiome has to manufacture it, and research suggests a meaningful share of people carry gut bacteria that make little or none. That variability is one reason a standardized supplement exists at all.

The reason urolithin A draws so much attention is a cellular process called mitophagy — the targeted removal and recycling of damaged mitochondria. When mitophagy slows with age, cells accumulate dysfunctional mitochondria that leak and underperform. In preclinical research (animal and cell studies, not human proof), Ryu et al. (2016, Nature Medicine) showed urolithin A restored mitophagy and improved muscle function in rodents and extended lifespan in the worm C. elegans. In humans, Andreux et al. (2019, Nature Metabolism) ran the first-in-human trial and found urolithin A was safe and well tolerated up to 1,000 mg/day and shifted a mitochondrial gene-expression signature in a favorable direction. Later human trials (Singh et al. 2022, Cell Reports Medicine; Liu/D'Amico et al. 2022, JAMA Network Open) reported improvements in muscle strength, endurance, or exercise performance in middle-aged and older adults over roughly four months.

What are NMN and NR?

NMN and NR are both building blocks the body uses to make NAD+ (nicotinamide adenine dinucleotide). NAD+ is a workhorse coenzyme — it shuttles electrons during energy metabolism and is consumed by repair and signaling enzymes called sirtuins and PARPs. NAD+ levels tend to fall with age, and the logic behind both supplements is straightforward: give the body more raw material and it can top the pool back up.

NR is the more thoroughly studied of the two in humans. Multiple randomized trials have shown that NR reliably raises blood NAD+ markers and is generally well tolerated. What human trials have been less consistent about is translating that NAD+ rise into clear functional outcomes — the “I can feel it” endpoints — which remains an active research question. NMN also raises NAD+ in human studies and has early trials touching on physical endurance and metabolic measures, though its human evidence base is still maturing and several results need replication.

The regulatory picture (this matters in 2026)

Here is a practical difference that often gets ignored. Urolithin A has a well-established U.S. regulatory footing: the branded ingredient used in clinical trials received FDA-reviewed GRAS (Generally Recognized As Safe) status for use in foods and supplements, which is part of why you see it sold openly and studied at defined doses.

NMN's status has been turbulent. In 2022 the FDA took the position that NMN was excluded from the dietary-supplement definition because it had been authorized for investigation as a drug, which pushed many products off shelves. Then in late September 2025 the FDA reversed course, confirming in letters responding to a citizen petition that NMN is not excluded from the definition of a dietary supplement. Importantly, NMN is still treated as a New Dietary Ingredient, meaning companies are expected to file New Dietary Ingredient Notifications, and the agency flagged that the determination could face future legal challenges. NR, by contrast, has carried accepted NDI and GRAS status for years without the same drama. None of this tells you which molecule “works better” — but it does affect availability, labeling confidence, and how settled each category is.

Head-to-head: how they actually differ

Mechanism

Urolithin A primarily supports mitophagy and overall mitochondrial quality. NMN and NR feed NAD+ synthesis. One clears damaged units; the others supply a coenzyme. These are complementary ideas, not competing ones.

Strength of human evidence

Urolithin A has a focused set of randomized human trials centered on muscle endurance, strength, and mitochondrial markers in middle-aged and older adults. NR has the deepest human record for raising NAD+ and strong safety data, with functional outcomes still being worked out. NMN has human NAD+ and early performance data but a less settled evidence base. In all three cases, the honest summary is “promising and still developing,” not “proven to do X for everyone.”

What people typically take them for

People reach for urolithin A mostly around muscle endurance, exercise recovery, and healthy-aging energy at the cellular level. People reach for NMN and NR mostly around the broad NAD+ decline story. Goals overlap, but the entry point differs.

Dosing and form

Urolithin A is studied at 500–1,000 mg/day. NR and NMN are commonly used in the few-hundred-milligram range. Forms vary widely — capsules, powders, softgels, and gummies — and quality and third-party testing matter far more than the format itself.

Can you combine them?

Because urolithin A and the NAD+ precursors act on different steps, some people use them together, and there is no established reason they would interfere with each other at normal supplement doses. That said, “they target different pathways” is a mechanistic argument, not proof that stacking produces an additive benefit in humans — that specific question has not been settled in rigorous trials. If you are considering combining supplements, or you take prescription medications, talk to your doctor or pharmacist first. More is not automatically better, and a cluttered routine you cannot sustain tends to beat itself.

How to choose

Start with the pathway that matches your goal. If your interest is muscle endurance, exercise capacity, and supporting the cell's ability to clear out worn mitochondria, urolithin A has the most directly relevant human trials and a settled regulatory footing. If your interest is specifically the NAD+ decline narrative, NR has the strongest and longest human track record for raising NAD+ with good tolerability, while NMN is the more regulatorily eventful option whose functional evidence is still catching up. Whatever you pick, favor products that disclose the exact dose, use a clinically studied amount, and publish third-party testing. For a deeper look at choosing a specific product, see our roundup of the best urolithin A gummies, and if you want the pairwise detail, read urolithin A vs NMN and urolithin A vs NR.

None of these molecules is a shortcut around the basics. Resistance training, aerobic work, protein-forward nutrition, and sleep remain the foundation of mitochondrial and muscle health; supplements are there to support that foundation, not replace it. Set a realistic timeline too — the human urolithin A trials ran for months, not days, so give any routine a fair, consistent trial before judging it.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.